Please wait
0001658247333-280407424B5EX-FILING FEESfalse 0001658247 2024-10-08 2024-10-08 0001658247 1 2024-10-08 2024-10-08 iso4217:USD xbrli:pure
Exhibit 107
Calculation of Filing Fee Tables
S-3
Crinetics Pharmaceuticals, Inc.
Table 1: Newly Registered and Carry Forward Securities
 
           
Security 
Type 
   
Security
Class
Title
   
Fee
Calculation
or Carry
Forward
Rule
   
Amount
Registered
   
Proposed
Maximum
Offering
Price Per
Unit
   
Maximum
Aggregate
Offering
Price
   
Fee Rate
   
Amount of 
Registration 
Fee 
     
Carry 
Forward 
Form 
Type 
   
Carry 
Forward 
File 
Number 
   
Carry 
Forward 
Initial 
Effective 
Date 
   
Filing Fee
Previously
Paid in
Connection
with
Unsold
Securities
to be
Carried
Forward
Newly Registered Securities
Fees to
be Paid
    1    Equity    Common Stock, par value $0.001 per share    457(r)   
11,500,000 
    $50.00    $575,000,000     0.00015310       $88,032.50     
 
   
 
   
 
   
 
Fees Previously Paid   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
 
   
 
   
 
   
 
   
 
Carry Forward Securities
Carry Forward Securities   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
 
   
 
   
 
   
 
   
 
 
   
 
   
 
    Total Offering Amounts:    
 
    $575,000,000   
 
      $88,032.50     
 
   
 
   
 
   
 
 
   
 
   
 
    Total Fees Previously Paid:    
 
   
 
   
 
      $
0.00
     
 
   
 
   
 
   
 
 
   
 
   
 
    Total Fee Offsets:    
 
   
 
   
 
      $
0.00
     
 
   
 
   
 
   
 
 
   
 
   
 
    Net Fee Due:    
 
   
 
   
 
      $
88,032.50
     
 
   
 
   
 
   
 
Offering Note
 
1
 
Calculated pursuant to Rule 457(r) unde
r th
e Securities Act of 1933, as amended (the “Securities Act”). The fee payable in connection with the offering pursuant to the prospectus supplement with which this Calculation of Filing Fee Tables is filed (the “prospectus supplement”) has been paid in accordance with Rule 456(b) under the Securities Act. The securities covered by this Calculation of Filing Fee Tables includes 1,500,000 shares of common stock that are issuable upon the underwriters’ exercise of their option to purchase
such s
hares for 30 days after the date of the prospectus supplement.
Narrative Disclosure
The maximum aggregate offering price of the securities to which the prospectus supplement relates is $575,000,000. The prospectus supplement is a final prospectus for the related offering.